This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $41.96 in the latest trading session, marking a +0.55% move from the prior day.
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
by Zacks Equity Research
Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study
by Zacks Equity Research
Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
by Zacks Equity Research
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval
by Zacks Equity Research
FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.
Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
by Zacks Equity Research
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.
Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
by Zacks Equity Research
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
by Zacks Equity Research
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.
Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction
by Zacks Equity Research
Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
by Zacks Equity Research
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review
by Swarup Gupta
The index endured a holiday-shortened but volatile week.
Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
by Zacks Equity Research
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
by Zacks Equity Research
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.